1. Remdesivir alone is not enough, researchers conclude in first major COVID-19 trial of the drug  CNN Philippines
  2. US govt agency study finds anti-viral drug effective against coronavirus  Rappler
  3. Covid-19 study details benefits of remdesivir treatment, and also limitations  STAT
  4. Setting the price for a drug  The Star Online
  5. COVID-19 Cure: Bangladesh Claims Success; Dr. Tarek Alam Who Is Behind Cure Speaks To India Today  India Today
  6. View Full coverage on Google News
Researchers have finally published the data that led the federal government to recommend the use of the antiviral drug remdesivir in very ill coronavirus patients, and they say the drug alone will not be enough to help patients.Researchers have finally published the data that led the federal government to recommend the use of the antiviral drug remdesivir in very ill coronavirus patients, and they say the drug alone will not be enough to help patients.

Remdesivir alone is not enough, researchers conclude in first major COVID-19 trial of the drug

Study suggests that remdesivir, when injected intravenously daily for 10 days accelerated the recovery of hospitalised COVID-19 patientsStudy suggests that remdesivir, when injected intravenously daily for 10 days accelerated the recovery of hospitalised COVID-19 patients

New study finds anti-viral drug remdesivir effective against coronavirus

Remdesivir sped the recovery time of patients with the disease, but its benefit appeared much more limited in patients who needed mechanical ventilation.Remdesivir sped the recovery time of patients with the disease, but its benefit appeared much more limited in patients who needed mechanical ventilation.

Covid-19 study details benefits of remdesivir treatment, and also limitations

A viral social media post falsely claims Dr. Anthony Fauci is "pushing" remdesivir as a potential COVID-19 treatment drug, because he "invented" it with Bill Gates and they stand to profit from it. Remdesivir was invented by the pharmaceutical company Gilead Sciences, which receives any profit from sales of the drug as a treatment for COVID-19.

Fauci Didn't Invent, Won't Profit from Remdesivir - FactCheck.org

FROM DR MARK CHEONG , School of Pharmacy Monash University MalaysiaFROM DR MARK CHEONG , School of Pharmacy Monash University Malaysia

Setting the price for a drug | The Star

“Maryland has now distributed 6,700+ vials of the antiviral drug remdesivir to hospitals statewide to help treat #COVID19 patients. I want to thank @HHSgov for their partnership as we direct this lifesaving treatment to the hardest-hit regions of our state.”

Governor Larry Hogan on Twitter: "Maryland has now distributed 6,700+ vials of the antiviral drug remdesivir to hospitals statewide to help treat #COVID19 patients. I want to thank @HHSgov for their partnership as we direct this lifesaving treatment to the hardest-hit regions of our state."

“Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug @ChandnaHimani reports #ThePrintHealth https://t.co/4YoT9f8Ymy”

Shekhar Gupta on Twitter: "Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug @ChandnaHimani reports #ThePrintHealth https://t.co/4YoT9f8Ymy"

“Indian pharmaceutical companies have taken a step forward towards bringing #remdesivir, a drug touted as a potential treatment for Covid-19, to India. ⁦@Cipla_Global⁩ and @HeteroLabs have sought a clinical trial waiver from the #DCGI https://t.co/zvflcxXmJ9”

Teena Thacker on Twitter: "Indian pharmaceutical companies have taken a step forward towards bringing #remdesivir, a drug touted as a potential treatment for Covid-19, to India. ⁦@Cipla_Global⁩ and @HeteroLabs have sought a clinical trial waiver from the #DCGI https://t.co/zvflcxXmJ9"

“Gilead Sciences statement on NEJM publication of Remdesivir data from NIAID study. (Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials. Its safety & efficacy for treatment of #COVIDー19 are not yet established.)”

Siddharth Zarabi on Twitter: "Gilead Sciences statement on NEJM publication of Remdesivir data from NIAID study. (Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials. Its safety & efficacy for treatment of #COVIDー19 are not yet established.)… https://t.co/eRqNsnetvz"

Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night,Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night,

Anti-viral drug effective against coronavirus, study finds

The country has gotten approval under World Trade Organization (WTO) provisions to produce generic versions of patented drugs.The country has gotten approval under World Trade Organization (WTO) provisions to produce generic versions of patented drugs.

Bangladesh Firm Becomes World's First Supplier Of Generic Drug Remdevisir For COVID-19 Treatment

Gilead’s remdesivir helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days.Remdesivir was the first medicine to be cleared for the treatment of Covid-19Gilead’s remdesivir helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days.Remdesivir was the first medicine to be cleared for the treatment of Covid-19

Gilead’s remdesivir mainly helped healthier coronavirus patients

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

NIH trial: Gilead's drug works best in COVID patients on oxygen - Reuters

Anti-viral remdesivir cuts COVID-19 recovery time, study saysAnti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America's top...

Anti-viral remdesivir cuts COVID-19 recovery time, study says | Daily Sabah

The drug helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo, according to the report in the New England Journal of Medicine.The drug helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo, according to the report in the New England Journal of Medicine.

Gilead’s remdesivir mainly helped healthier COVID-19 patients | coronavirus outbreak News,The Indian Express

Patients taking remdesivir had a median recovery time of 11 days compared to 15 days for those taking a placeboPatients taking remdesivir had a median recovery time of 11 days compared to 15 days for those taking a placebo

Peer-Reviewed Data Shows Remdesivir Shortened Covid-19 Recovery Time

Preliminary results from NIH clinical trial published.Preliminary results from NIH clinical trial published.

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery | National Institutes of Health (NIH)

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the Nati

Remdesivir Improves Time to Recovery for COVID-19 in New England Journal of Medicine Study

Remdesivir Improves Time to Recovery for COVID-19 in New England Journal of Medicine Study – SciTechDaily

The peer-reviewed data was published in the New England Journal of Medicine. The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31%, compared to placebo patients. The biggest benefit was seen in patientsThe peer-reviewed data was published in the New England Journal of Medicine. The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31%, compared to placebo patients. The biggest benefit was seen in patients

NIH trial: Gilead's drug works best in COVID patients on oxygen

There are no reliable, safe, and effective antiviral drugs or COVID-19 vaccines that will be made available in the next two years. Therefore, it is important to build up one’s immune system using vitamin C and other antioxidants, even as we develop...There are no reliable, safe, and effective antiviral drugs or COVID-19 vaccines that will be made available in the next two years. Therefore, it is important to build up one’s immune system using vitamin C and other antioxidants, even as we develop...

Norris McDonald | Healthy eating saves lives - COVID-19 and the politics of medicine | Commentary | Jamaica Gleaner

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

In hospitalized patients with severe COVID-19, the antiviral drug remdesivir reduced recovery time by about one-third, a large, multinational trial has found. Preliminary results were published today in the New England Journal of Medicine.In hospitalized patients with severe COVID-19, the antiviral drug remdesivir reduced recovery time by about one-third, a large, multinational trial has found. Preliminary results were published today

Remdesivir speeds recovery in cases of severe COVID-19 | Newsroom

Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.

Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug

Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.

Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug

However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drugHowever, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug

US govt agency study finds anti-viral drug effective against coronavirus

A research group led by the US National Institute of Heath has concluded the drug remdesivir helps shorten recovery time for COVID-19 patients.A research group led by the US National Institute of Heath has concluded the drug remdesivir helps shorten recovery time for COVID-19 patients.

US team concludes shorter recovery with remdesivir | NHK WORLD-JAPAN News

Contrarians are saying that while remdesivir can save lives, it will likely be nothing more than a one-time bonus to Gilead's bottom line. Here's why.Contrarians are saying that while remdesivir can save lives, it will likely be nothing more than a one-time bonus to Gilead's bottom line. Here's why.

Before You Buy Gilead Sciences Stock, Read This | The Motley Fool

The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.

Remdesivir cuts recovery time of Covid patients from 15 days to 11: New peer-reviewed study

The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.

Remdesivir cuts recovery time of Covid patients from 15 days to 11: New peer-reviewed study

More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US.More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US.

Remdesivir tops list of Covid-19 drug contenders, say scientists - india news - Hindustan Times

As COVID-19 continues its spread -- crossing 5.2 million cases and 3,38,000 fatalities on Saturday -- several categories of drugs are under clinical trial.As COVID-19 continues its spread -- crossing 5.2 million cases and 3,38,000 fatalities on Saturday -- several categories of drugs are under clinical trial.

Several drugs under trial for COVID-19, remdesivir leading contender: Scientists - Moneycontrol.com

Beximco Pharmaceuticals to give drug, which has been authorised by the US for emergency use in the treatment of coronavirus patients, for free to state-...Beximco Pharmaceuticals to give drug, which has been authorised by the US for emergency use in the treatment of coronavirus patients, for free to state-...

Bangladesh pharma giant to sell first generic version of remdesivir for Covid-19 - News | Khaleej Times

Two thirds of patients UIHC has enrolled in its trial have recovered and been released.

Remdesivir: The Race for Relief and how UIHC is involved

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

NIH trial: Gilead's drug works best in COVID patients on oxygen

Access Denied

BANGALORE (REUTERS) - The US National Institutes of Health (NIH) said on Friday (May 22) peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences' remdesivir is effective at helping Covid-19 patients recover.. Read more at straitstimes.com.United States News -BANGALORE (REUTERS) - The US National Institutes of Health (NIH) said on Friday (May 22) peer-reviewed data published in the New England Journal of Medicine show that Gilead

Peer-reviewed data shows Gilead's drug effective against Covid-19, United States News & Top Stories - The Straits Times

Gilead Sciences Inc.'s antiviral drug remdesivir improved COVID-19 patients' recovery time in peer-reviewed data from a study by the National Institute of...Gilead Sciences Inc.'s antiviral drug remdesivir improved COVID-19 patients' recovery time in peer-reviewed data from a study by the National Institute of...

Gilead's remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID says - MarketWatch

Read more about First copies of Gilead coronavirus drug to start selling in Bangladesh on Business Standard. The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitalsThe Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

First copies of Gilead coronavirus drug to start selling in Bangladesh | Business Standard News

The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suitThe United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit

Study: Anti-viral drug effective against coronavirus | Dhaka Tribune

Remdesivir has recently been authorised by the US for emergency use in the treatment of COVID-19 patients.Remdesivir has recently been authorised by the US for emergency use in the treatment of COVID-19 patients.

Bangladesh pharma giant introduces first generic version of remdesivir for COVID-19- The New Indian Express

Beximco Pharmaceuticals yesterday handed over the first batch of its antiviral drug remdesivir that has shown the most promise in treating Covid-19 patients by cutting the duration of symptoms from 15 days to 11. The delivery took place on the day the drug administration gave emergency authorisation to the company to market the drug with the brand name Bemsivir IV.Beximco Pharmaceuticals yesterday handed over the first batch of its antiviral drug remdesivir that has shown the most promise in treating Covid-19 patients by cutting the duration of symptoms from

Beximco hands over first batch of remdesivir to govt | The Daily Star

Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America’s top infectious diseases expert said the study showed the medication has “clear-cut” benefits. Complete results from the research, which was carried out by US government agency the National Institute of Allergy […]

‘Clear-cut, significant and positive effect’: Anti-viral drug effective against coronavirus, study finds – Raw Story

Remdesivir could be the first real treatment for COVID-19 that finally gives humans even a slight upper hand against the microbe.Remdesivir was initally investigated as a treatment for another lethal viral disease, Ebola

How Remdesivir Moved From Back Shelf to Best Hope for COVID | Time

Beximco Pharmaceuticals has launched the first generic version of antiviral drug remdesivir, which was originally developed by Gilead Sciences.

Beximco Pharmaceuticals launches first generic remdesivir for Covid-19

Preliminary information showed remdesivir has promising results in shortening the duration of COVID-19 by about a third. But there are still questions about the drug's risks and side effects.Preliminary information showed remdesivir has promising results in shortening the duration of COVID-19 by about a third. But there are still questions about the drug's risks and side effects.

Remdesivir Arrives In D.C. Region, Bringing Possible Help In Treating COVID-19 | DCist

Just a moment...

The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised COVID-19 patients.The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised COVID-19 patients.

U.S. pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India - The Hindu

Bangladeshi firm debuts world’s first generic remdesivir for COVID-19 treatment

Bangladeshi firm debuts world’s first generic remdesivir for COVID-19